  See all
|
Article Summary
|
|
|
New threats to drug makers' revenues are rising even as the industry maneuvers to plug huge holes from looming patent expirations. A newly elected U.S. administration under President-elect Barack Obama brings concerns over pricing and further potential scrutiny, at a time when drug companies have already faced increased uncertainty from the regulators of their products.
--- REGULATORY ISSUES TOP ARTICLES ---
Receive free subspecialty "5-minute updates" via email
|
 |
|
Read a Different Specialty |
|
|
|
|
|
Profession Index
|
|
|
|
|
|
|
|
